Ana Arance

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8567947/publications.pdf

Version: 2024-02-01

75 papers	21,737 citations	94433 37 h-index	95266 68 g-index
79 all docs	79 docs citations	79 times ranked	22547 citing authors

#	Article	IF	Citations
1	Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib forBRAFV600â€“Mutant Unresectable or Metastatic Melanoma. Journal of Clinical Oncology, 2022, 40, 1428-1438.	1.6	90
2	Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. New England Journal of Medicine, 2022, 386, 24-34.	27.0	766
3	Clinical Models to Define Response and Survival With Antiâ€“PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. Journal of Clinical Oncology, 2022, 40, 1068-1080.	1.6	43
4	Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival. Cancers, 2022, 14, 1237.	3.7	7
5	Abstract P2-13-21: Improved central nervous system outcomes in patients with early-stage HER2-positive breast cancer who receive neratinib for the recommended duration: Findings from the phase 3 ExteNET trial. Cancer Research, 2022, 82, P2-13-21-P2-13-21.	0.9	1
6	Initial Stage of Cutaneous Primary Melanoma Plays a Key Role in the Pattern and Timing of Disease Recurrence. Acta Dermato-Venereologica, 2021, 101, adv00502.	1.3	13
7	A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III). Cancers, 2021, 13, 2466.	3.7	7
8	Safe anti-programmed cell death-1 rechallenge with antibody switching after immune-related adverse events: brief communication. Immunotherapy, 2021, 13, 745-752.	2.0	2
9	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). European Journal of Cancer, 2021, 152, 116-128.	2.8	7
10	Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East. International Journal of Cancer, 2021, 149, 1926-1934.	5.1	8
11	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. , 2021, 9, e003188.		12
12	Molecular Markers and Targets in Melanoma. Cells, 2021, 10, 2320.	4.1	72
13	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. European Journal of Cancer, 2021, 157, 391-402.	2.8	13
14	Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. Nature Communications, 2021, 12, 7008.	12.8	22
15	Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600â€“mutant melanoma. European Journal of Cancer, 2020, 126, 33-44.	2.8	130
16	Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma. Journal of Clinical Oncology, 2020, 38, 3937-3946.	1.6	119
17	Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nature Medicine, 2020, 26, 1557-1563.	30.7	78
18	Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma. JAMA Oncology, 2020, 6, 1256.	7.1	38

#	Article	IF	Citations
19	TP53 mutation and tumoral PD-L1 expression are associated with depth of invasion in desmoplastic melanomas. Annals of Translational Medicine, 2020, 8, 1218-1218.	1.7	7
20	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. , 2020, 8, e000391.		39
21	Successful management of refractory immune-mediated enterocolitis with cyclosporine. European Journal of Cancer, 2020, 131, 37-39.	2.8	4
22	Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.. Journal of Clinical Oncology, 2020, 38, 10012-10012.	1.6	14
23	Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma.. Journal of Clinical Oncology, 2020, 38, 10013-10013.	1.6	23
24	The antiâ€“PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600â€“mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.. Journal of Clinical Oncology, 2020, 38, 10028-10028.	1.6	8
25	Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600â€“mutant melanoma.. Journal of Clinical Oncology, 2020, 38, 10034-10034.	1.6	2
26	The antiâ€“PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600â€“mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I.. Journal of Clinical Oncology, 2020, 38, 57-57.	1.6	7
27	Implementation of an NGS panel for clinical practice in paraffin-embedded tissue samples from locally advanced and metastatic melanoma patients. , 2020, 1, 101-108.		4
28	Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600â€“mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T).. Journal of Clinical Oncology, 2020, 38, 39-39.	1.6	0
29	Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, courseÂand management. European Journal of Cancer, 2019, 119, 97-106.	2.8	75
30	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncology, The, 2019, 20, 1239-1251.	10.7	812
31	Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncology, The, 2019, 20, 1083-1097.	10.7	611
32	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Annals of Oncology, 2019, 30, 766-773.	1.2	78
33	Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. JAMA Oncology, 2019, 5, 187.	7.1	295
34	Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600â€“mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T).. Journal of Clinical Oncology, 2019, 37, 9515-9515.	1.6	2
35	Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. European Journal of Cancer, 2018, 91, 116-124.	2.8	69
36	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology, The, 2018, 19, 603-615.	10.7	751

#	Article	IF	Citations
37	Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 1315-1327.	10.7	469
38	Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 435-445.	10.7	399
39	Immune-Related Gene Expression Profiling After PD-1 Blockade in Nonâ€“Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. Cancer Research, 2017, 77, 3540-3550.	0.9	327
40	Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma. Clinical Cancer Research, 2017, 23, 5339-5348.	7.0	142
41	Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncology, The, 2017, 18, 863-873.	10.7	561
42	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncology, The, 2017, 18, 611-622.	10.7	428
43	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet, The, 2017, 390, 1853-1862.	13.7	1,032
44	Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study). Oncologist, 2017, 22, 951-962.	3.7	13
45	Dabrafenib plus trametinib for compassionate use in metastatic melanoma. Medicine (United States), 2017, 96, e9523.	1.0	6
46	Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM). Annals of Translational Medicine, 2017, 5, 390-390.	1.7	0
47	Development of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK Inhibitors. Acta Dermato-Venereologica, 2017, 97, 258-260.	1.3	9
48	Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.. Journal of Clinical Oncology, 2017, 35, 9504-9504.	1.6	53
49	COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600â€“mutant (mut) melanoma brain metastases (MBM).. Journal of Clinical Oncology, 2017, 35, 9506-9506.	1.6	10
50	Real life outcome of advanced melanoma patients who discontinue pembrolizumab (PEMBRO) in the absence of disease progression.. Journal of Clinical Oncology, 2017, 35, 9539-9539.	1.6	4
51	Blood eosinophil counts as predictive marker in advanced melanoma patients treated with anti-PD1 therapies.. Journal of Clinical Oncology, 2017, 35, 66-66.	1.6	0
52	Infomelanoma 2020: an online digital application designed to assist health professionals for melanoma treatment. Annals of Translational Medicine, 2017, 5, 392-392.	1.7	0
53	Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis. ESMO Open, 2016, 1, e000032.	4.5	7
54	Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab. Immunotherapy, 2016, 8, 687-692.	2.0	7

#	Article	IF	Citations
55	Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma. Future Oncology, 2016, 12, 2683-2688.	2.4	17
56	Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006.. Journal of Clinical Oncology, 2016, 34, 9504-9504.	1.6	44
57	Pembrolizumab expanded access program (EAP) in Spain: clinical activity.. Journal of Clinical Oncology, 2016, 34, e21029-e21029.	1.6	0
58	Association of response to programmed death 1 receptor or ligand (PD1/PDL1) blockade with immune-related gene expression profiling across three cancer-types.. Journal of Clinical Oncology, 2016, 34, 3038-3038.	1.6	0
59	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet, The, 2015, 386, 444-451.	13.7	1,175
60	Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. BMC Medicine, 2015, 13, 303.	5.5	113
61	Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer. Clinical Breast Cancer, 2015, 15, 8-15.	2.4	47
62	Nivolumab in Previously Untreated Melanoma withoutBRAFMutation. New England Journal of Medicine, 2015, 372, 320-330.	27.0	4,795
63	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. European Journal of Cancer, 2015, 51, 833-840.	2.8	71
64	Pembrolizumab versus Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2015, 372, 2521-2532.	27.0	4,838
65	Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast, 2015, 24, S26-S35.	2.2	735
66	Frequency and Characteristics of Familial Melanoma in Spain: The FAM-GEM-1 Study. PLoS ONE, 2015, 10, e0124239.	2.5	8
67	A randomized, openâ€label clinical trial of tasisulam sodium versus paclitaxel as secondâ€line treatment in patients with metastatic melanoma. Cancer, 2014, 120, 2016-2024.	4.1	19
68	Ipilimumab for advanced melanoma. Melanoma Research, 2014, 24, 577-583.	1.2	38
69	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. New England Journal of Medicine, 2014, 371, 1877-1888.	27.0	1,572
70	Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncology, The, 2014, 15, 436-444.	10.7	242
71	Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncology, The, 2013, 14, 733-740.	10.7	151
72	Ability to Acquire Drug Resistance Arises Early during the Tumorigenesis Process. Cancer Research, 2007, 67, 1130-1137.	0.9	53

#	Article	IF	Citations
73	Assessing outcomes in palliative chemotherapy. Expert Opinion on Pharmacotherapy, 2002, 3, 693-700.	1.8	5
74	Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma. Cancer, 2001, 92, 601-608.	4.1	49
75	O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: Results of a phase II study. International Journal of Cancer, 2000, 88, 469-473.	5.1	66